Target | Agent, mechanism | Cancer | Phase | National Clinical Trial (NCT) no. | Status |
TLR2 | CBLB612, agonist | Breast | 2 | NCT02778763 | C |
TLR3 | Poly ICLC, agonist | Brain and central nervous system | 2 | NCT00058123 | C |
1/2 | NCT01920191 | C | |||
Colorectal | 2 | NCT00773097 | C | ||
Fallopian tube, ovarian, peritoneal | 1/2 | NCT02166905 | C | ||
Glioblastoma | 2 | NCT00262730 | C | ||
1/2 | NCT02078648 | C | |||
Glioma | 2 | NCT01188096 | C | ||
1/2 | NCT00766753 | C | |||
Head and neck, skin | 2 | NCT02423863 | C | ||
Melanoma | 1/2 | NCT01079741 | C | ||
Myeloma | 2 | NCT01245673 | C | ||
NY-ESO-1+ malignancies | 1/2 | NCT00948961 | C | ||
Solid tumors | 2 | NCT01734564 | C | ||
Rintatolimod, agonist | Breast | 1/2 | NCT01355393 | C | |
Fallopian tube, ovarian, peritoneal | 1/2 | NCT01312389 | C | ||
Peritoneal | 1/2 | NCT02151448 | C | ||
TLR 7/8 | Imiquimod, agonist | Anal | 3 | NCT02059499, NCT02135419 | A |
Basal cell | 3 | NCT00066872, NCT00129519, NCT00189241, NCT00189280, NCT00189306, NCT01212549 | C | ||
NCT02242929 | A | ||||
2/3 | NCT02029352 | C | |||
Bladder | 2 | NCT01731652 | C | ||
Breast | 2 | NCT00821964, NCT00899574 | C | ||
1/2 | NCT01421017 | C | |||
Cervical | 2/3 | NCT00941252, NCT02130323 | C | ||
2 | NCT00031759, NCT03233412 | C | |||
Colorectal | 1/2 | NCT00785122 | C | ||
Lentigo maligna (melanoma) | 3 | NCT01720407, NCT02394132 | A | ||
2/3 | NCT01088737 | A | |||
Melanoma | 2 | NCT00273910, NCT00651703 | C | ||
Non-small cell lung | 2 | NCT00442754, NCT01909752 | C | ||
Prostate | 2 | NCT02293707 | C | ||
Resiquimod, agonist | Cutaneous T-cell lymphoma | 1/2 | NCT01676831 | C | |
Melanoma | 2 | NCT00960752 | C | ||
NY-ESO-1+ malignancies | 1/2 | NCT00948961 | C | ||
852A, agonist | Breast, cervical, endometrial, ovarian | 2 | NCT00319748 | C | |
Melanoma | 2 | NCT00189332 | C | ||
VTX-2337, agonist | Fallopian tube, ovarian, peritoneal | 2 | NCT01666444 | C | |
Head & neck | 2 | NCT01836029 | C | ||
TLR 7/8/9 | IMO-8400, inhibitor | Diffuse large B-cell lymphoma | 1/2 | NCT02252146 | C |
Waldenstrom’s macroglobulinemia | 1/2 | NCT02363439 | C | ||
MGN1703, agonist | Colorectal | 3 | NCT02077868 | A | |
2 | NCT01208194 | C | |||
Small cell lung | 2 | NCT02200081 | C | ||
TLR9 | CPG 7909, agonist | Breast | 2 | NCT00043394 | C |
1/2 | NCT00031278 | C | |||
Breast, melanoma, non-small cell lung, renal, T-cell lymphoma | 2 | NCT00043368 | C | ||
B-cell lymphoma | 2 | NCT00880581, NCT00490529 | C | ||
Cutaneous T-cell lymphoma, non-Hodgkin’s lymphoma | 1/2 | NCT00185965, NCT00043420, NCT00438880 | C | ||
Melanoma | 2 | NCT00070642, NCT00085189, NCT01266603 | C | ||
Non-small cell lung | 2 | NCT00070629 | C | ||
Renal | 1/2 | NCT00043407 | C | ||
EMD 1201081/IMO-2055, Agonist | Head and neck | 2 | NCT01040832 | C | |
Renal | 2 | NCT00729053 | C | ||
IMO-2125, agonist | Melanoma | 3 | NCT03445533 | A | |
1/2 | NCT02644967 | C | |||
SD-101, agonist | B-cell lymphoma | 1/2 | NCT02254772 | C |
Source: https://clinicaltrials.gov.
A, active trial; C, completed trial; no., number; NY-ESO-1, New York Esophageal Squamous Cell Carcinoma-1, tumor antigen; TLR, Toll-like receptor.